Calciphylaxis Diagnosis and Management in Primary Care
Author reviews calciphylaxis incidence, risk factors, pathogenesis, differential diagnoses, and treatment.
Kidney Disease
SGLT2 Inhibitors Lead to Favorable Renal, CV Outcomes in Type 2 Diabetes
Using certain glucose inhibitors in people with type 2 diabetes may also have a beneficial effect on renal and cardiovascular health, and weight.
Pre-Dialysis Hyperkalemia Common in the Hemodialysis Population
Nearly 74% of hemodialysis patients experienced pre-dialysis hyperkalemia within 1 year of enrollment in the Dialysis Outcomes and Practice Patterns Study, according to investigators.
Calciphylaxis Prevention and Treatment Strategies
Calciphylaxis treatment should include a multimodal approach with a focus on supportive care, infection prevention, pain management, and wound healing.
Pregnancy Found to Increase Risk of First-Time Symptomatic Kidney Stones
The risk for a first-time symptomatic kidney stone begins to increase in the second trimester and peaks 0 to 3 months after delivery, a study findings suggest.
Zinc Deficiency May Up Infection-Related Hospitalizations in Advanced CKD
Nearly 80% of patients in a recent study had very low serum zinc values, which raises concern for the advanced CKD population at large, according to investigators.
Waitlist Placement, Kidney Transplant Rates Not Improving
For patients with end-stage kidney disease, there has been little improvement in rates of waitlist placement or transplantation since 1997.
NSAIDs May Increase AKI, Hyperkalemia Risks in Diabetes
Study findings suggest NSAIDs may be a risk factor for acute kidney injury and hyperkalemia in patients with diabetes.
Hematopoietic Stem Cell Transplantation May Not Reduce Renal Function in Sickle Cell Disease
For patients with sickle cell disease, HSCT may not be associated with a significant increase in CKD incidence or prevalence following transplantation.
Canagliflozin Beneficial Even for Advanced Kidney Disease
Treatment with the sodium glucose cotransporter 2 (SGLT2) inhibitor canagliflozin can reduce rates of kidney disease progression.
- Loading...
Loading...
Next post in Nephrology Information Center
Loading... 
Loading...